Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 4/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.32 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | IDH1 | O75874 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29956567 | 1.00 | CLK4 (0.39) | CLK4KDM4CCA1CA2GRM4 | |
| SCHEMBL27751609 | 0.80 | MAP4K4 (0.44) | CA1CA2EGLN2 | |
| SCHEMBL29951370 | 0.80 | HDAC8 (0.41) | CA1CA2CDC7CDK2MAP3K14 | |
| SCHEMBL931149 | 0.80 | MAP3K14 (0.39) | CLK4KDM4CCYP2A6KCNH2NPY5R | |
| SCHEMBL2107129 | 0.76 | GRM5 (0.45) | CA1CA2GRM4 | |
| SCHEMBL19962828 | 0.74 | IDH1 (0.39) | CLK4KDM4CGRM4ALDH1A1IDH1 | |
| SCHEMBL22637043 | 0.73 | CLK4 (0.34) | CLK4KCNH2NPY5RALDH1A1EGLN2 | |
| SCHEMBL28543643 | 0.73 | MEN1 (0.53) | CLK4GRM4CDC7CDK2ALDH1A1 | |
| SCHEMBL2528059 | 0.72 | — | — | |
| SCHEMBL7970820 | 0.72 | MAPKAPK2 (0.40) | CLK4KDM4CKCNH2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271090-A | Method for improving isostatic graphite and isostatic graphite prepared by same | 湖南德智新材料有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-118271090-A | Method for improving isostatic graphite and isostatic graphite prepared by same | 湖南德智新材料有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4387964-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023192989-A2 | PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS | AZKARRA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | Prism BioLab Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2023027948-A1 | JAK2 INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-6043248-A | VIRICIDES FOR TREATING AN INDIVIDUAL INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0342577-B1 | Use of dihydropyridine derivatives for the prophylaxis or treatment of cerebral circulation disorders | YOSHITOMI PHARMACEUTICAL (JP) | 2000-03-15 | — | — | EP | disclosed |
| EP-0824524-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035678-A1 | ALPHA-SUBSTITUTED PYRIMIDINE-THIOALKYL AND ALKYLETHER COMPOUNDS AS INHIBITORS OF VIRAL REVERSE TRANSCRIPTASE | PHARMACIA & UPJOHN COMPANY (US) | 1996-11-14 | — | — | WO | disclosed |
| EP-0257616-B1 | DIHYDROPYRIDINE DERIVATES AND PHARMACEUTICAL COMPOSITION THEREOF | THE GREEN CROSS CORPORATION (JP) | 1992-10-28 | — | — | EP | disclosed |
| US-4910195-A | Containing carboxylated group in position 3 | GREEN CROSS CORPORATION (JP) | 1990-03-20 | — | — | US | disclosed |
| US-4886819-A | TREATMENT OF HYPERTENSION AND PROPHYLAXIS | THE GREEN CROSS CORPORATION (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0342577-A2 | Use of dihydropyridine derivatives for the prophylaxis or treatment of cerebral circulation disorders | THE GREEN CROSS CORPORATION (JP) | 1989-11-23 | — | — | EP | disclosed |
| EP-0265947-A2 | Dihydropyridine derivatives, process for their preparation, pharmaceutical composition and use | GREEN CROSS CORPORATION (JP) | 1988-05-04 | — | — | EP | disclosed |
| EP-0257616-A2 | Dihydropyridine derivates and pharmaceutical composition thereof | THE GREEN CROSS CORPORATION (JP) | 1988-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | CLK4 2854/4885KDM4C 2354/4885CA1 4733/4885 |
| US-20230265104-A1 | NOVEL HETEROCYCLIC COMPOUNDS | MKI67, CCNI, KRAS | CLK4 2916/4885KDM4C 1146/4885CA1 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.